Samsung Biologics to acquire PolyPeptide in $1.81bn cash deal
Completion of the deal is anticipated towards the end of 2026.
Drug Development
Aptar unveils framework for injectable drug delivery systems
FDA grants traditional approval to Novartis’ Fabhalta for IgAN
JCVI issues recommendation on adolescent MenB vaccination in UK
Telix opens radiopharmaceutical facility in Australia for cancer treatment
Harbour BioMed and Kelun-Biotech receive China IND approval for asthma therapy
FDA grants priority review to Roche’s Gazyva/Gazyvaro for pMN
Innovent licenses IBI355 rights to Spero for up to $1.1bn
